Myocardial Infarction (MI) Therapeutics Market by Product and Geography - Forecast and Analysis 2022-2026

The myocardial infarction (MI) therapeutics market share is expected to increase by USD 2.02 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 4.72%.

This MI therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers myocardial infarction (MI) therapeutics market segmentation by product (antithrombotics, vasodilators, thrombolytics, and others) and geography (North America, Asia, Europe, and Rest of World (ROW)).

What will the Myocardial Infarction (MI) Therapeutics Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Myocardial Infarction (MI) Therapeutics Market Size for the Forecast Period and Other Important Statistics

The MI therapeutics market report also offers information on several market vendors, including Amgen Inc., AstraZeneca Plc, Athera Biotechnologies AB, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., CeleCor Therapeutics, CHIESI Farmaceutici SpA, CSL Ltd., Eli Lilly and Co., Ever Supreme Bio Technology, F. Hoffmann La Roche Ltd., Faraday Pharmaceuticals, Idorsia Pharmaceuticals Ltd., Merck and Co. Inc., Mesoblast Ltd., Novartis AG, Pfizer Inc., Sanofi SA, and Johnson and Johnson Inc. among others. 

Myocardial Infarction (MI) Therapeutics Market: Key Drivers, Trends, and Challenges

The rising incidence of mi is notably driving the myocardial infarction (MI) therapeutics market growth, although factors such as extensive use of generics may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the myocardial infarction (MI) therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Myocardial Infarction (MI) Therapeutics Market Driver 

One of the key factors driving the global myocardial infarction (MI) therapeutics market growth is the rising incidence of MI. Novel antithrombotics such as NOACs and antiplatelet drugs such as Effient offer significant advantages, such as target specificity. Some of the examples under this category include edoxaban (LIXIANA), rivaroxaban, and apixaban (ELIQUIS). Andexxa by Portola Pharmaceuticals is the first and only antidote indicated for the treatment of uncontrolled bleeding caused by rivaroxaban and apixaban. Furthermore, in developed nations, reimbursement programs aim at providing full-time coverage for drug therapies as well as cardiovascular imaging and acute care. For instance, the CMS is a government agency in the US that covers medical services that are reasonable and necessary for the diagnosis or treatment of cardiovascular diseases, including MI, through its Medicare program. Hence, the availability of such reimbursement schemes is contributing to the growth of the market in the forecast period.

Key Myocardial Infarction (MI) Therapeutics Market Trend

Another key factor driving the global myocardial infarction (MI) therapeutics market growth is the increasing risk factors for MI. There are several risk factors that are associated with MI, such as cigarette smoking and hypertension. A study conducted by Prasad G. Jamkhande in November 2013 reports that cigarette smoking increases the risk of developing atherosclerosis by 50% and doubles the incidence of CHD. Cigarette smoking makes the arterial walls stiff, increases the fibrinogen level, decreases the high-density lipoprotein (HDL) cholesterol level, increases platelet aggregation, and boosts hematocrit. While, the sheering force associated with hypertension leads to the activation of the endothelium to induce genetic expressions such as procoagulant, inflammatory, and other responses that affect the endothelium and the blood vessel wall. Such factors are expected to accelerate the demand for MI therapeutics, which will positively impact the market growth in the forecast period.

Key Myocardial Infarction (MI) Therapeutics Market Challenge

One of the key challenges to the global myocardial infarction (MI) therapeutics market growth is the extensive use of generics. Generic drugs are allowed for sale after the expiry of the patent of the original branded drug. Thus, generic drugs have comparatively lower prices than branded drugs. Hence, the loss of patent exclusivities is a major challenge for the manufacturers of branded drugs as it provides fair opportunities for the development of generic drugs. The market is already flooded with the generic drugs that are used for the treatment of MI. Moreover, the high success rates associated with implantable cardioverter defibrillators (ICDs) and vest prevention of early sudden death trial (VEST) have led to their increased adoption rate among end-users, which, in turn, limits the use of MI therapeutics to a certain extent among patients, thereby restricting the market growth.

This myocardial infarction (MI) therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Who are the Major Myocardial Infarction (MI) Therapeutics Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• Amgen Inc.
• AstraZeneca Plc
• Athera Biotechnologies AB
• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Co.
• CeleCor Therapeutics
• CHIESI Farmaceutici SpA
• CSL Ltd.
• Eli Lilly and Co.
• Ever Supreme Bio Technology
• F. Hoffmann La Roche Ltd.
• Faraday Pharmaceuticals
• Idorsia Pharmaceuticals Ltd.
• Merck and Co. Inc.
• Mesoblast Ltd.
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Johnson and Johnson Inc.

 

This statistical study of the myocardial infarction (MI) therapeutics market encompasses successful business strategies deployed by the key vendors. The myocardial infarction (MI) therapeutics market is fragmented and the vendors are deploying growth strategies such as investment in R&D to compete in the market.

Product Insights and News

•  Amgen Inc.- The company offers myocardial infarction therapeutics such as Repatha.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The myocardial infarction (MI) therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Which are the Key Regions for Myocardial Infarction (MI) Therapeutics Market?

For more insights on the market share of various regions Request for a FREE sample now!

39% of the market's growth will originate from North America during the forecast period. US and Mexico are the key markets for myocardial infarction (MI) therapeutics in North America. Market growth in this region will be faster than the growth of the market in Asia and the Rest of World (ROW).

The significant increase in the incidence of MI, the availability of reimbursement schemes, and the increase in demand for antithrombotic drugs will facilitate the myocardial infarction (MI) therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

 A substantial rise in the number of COVID-19 cases in the first quarter of 2020 and early 2021 led to partial lockdowns in several countries, including Canada and Mexico. Thus, various non-urgent treatments and clinical visits were either limited or completely halted as per government guidelines. Hence, the sales of MI therapeutics declined slightly through offline medical stores; however, the pandemic also led to an increase in the use of e-commerce channels, which, in turn, led to a rise in the demand for MI therapeutics through online channels. Like many other pharmaceutical products, MI therapeutics were made available to the public through both online and offline channels. Thus, the regional market will register growth during the forecast period.

Myocardial Infarction (MI) Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the myocardial infarction (MI) therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Parent Market Analysis

Technavio categorizes the global myocardial infarction (MI) therapeutics market as a part of the pharmaceutical market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the myocardial infarction (MI) therapeutics market during the forecast period.

What are the Revenue-generating Product Segments in the Myocardial Infarction (MI) Therapeutics Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The myocardial infarction (MI) therapeutics market share growth by the antithrombotics segment will be significant during the forecast period. The growth of this segment can be attributed to the rising demand for NOACs throughout the world. NOACs specifically target key proteases such as factors IIa and Xa that are responsible for the formation of clots. 

This report provides an accurate prediction of the contribution of all the segments to the growth of the myocardial infarction (MI) therapeutics market size and actionable market insights on post COVID-19 impact on each segment.

 

Myocardial Infarction (MI) Therapeutics Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 4.72%
Market growth 2022-2026	$ 2.02 billion
Market structure	Fragmented
YoY growth (%)	4.4
Regional analysis	North America, Asia, Europe, and Rest of World (ROW)
Performing market contribution	North America at 39%
Key consumer countries	US, Mexico, Germany, UK, and China
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Amgen Inc., AstraZeneca Plc, Athera Biotechnologies AB, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., CeleCor Therapeutics, CHIESI Farmaceutici SpA, CSL Ltd., Eli Lilly and Co., Ever Supreme Bio Technology, F. Hoffmann La Roche Ltd., Faraday Pharmaceuticals, Idorsia Pharmaceuticals Ltd., Merck and Co. Inc., Mesoblast Ltd., Novartis AG, Pfizer Inc., Sanofi SA, and Johnson and Johnson Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Myocardial Infarction (MI) Therapeutics Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive myocardial infarction (MI) therapeutics market growth during the next five years
• Precise estimation of the myocardial infarction (MI) therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the myocardial infarction (MI) therapeutics industry across North America, Asia, Europe, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of myocardial infarction (MI) therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch